Remote control of macrophage production by cancer

OncoImmunology

Volumn 2, Issue 5, 2013, Pages

  Cortez Retamozo, Virna ^a   Engblom, Camilla ^a   Pittet, Mikael J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiotensin II; Cancer; Hematopoietic stem cell; Lung adenocarcinoma; Macrophage; Monocyte; NSCLC

Indexed keywords

ANGIOTENSIN II; ENALAPRIL; LOSARTAN;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL POPULATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; HUMAN; IMMUNOLOGICAL TOLERANCE; MALIGNANT NEOPLASTIC DISEASE; MYELOID PROGENITOR CELL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84886943326     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24183     Document Type: Article

References (10)

1. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141:39-51; PMID:20371344; http://dx.doi.org/10.1016/j. cell.2010.03.014
2. Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70:5728-39; PMID:20570887; http://dx.doi.org/10.1158/0008-5472.CAN-09-4672
3. Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, et al. Origins of tumorassociated macrophages and neutrophils. Proc Natl Acad Sci U S A 2012; 109:2491-6; PMID:22308361; http://dx.doi.org/10.1073/pnas.1113744109
4. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325:612-6; PMID:19644120; http://dx.doi.org/10.1126/science. 1175202
5. Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep 2012; 2:628-39; PMID:22959433; http://dx.doi.org/10.1016/j.celrep.2012.08.006
6. Cortez-Retamozo V, Etzrodt M, Newton A, Ryan R, Pucci F, Sio SW, et al. Angiotensin II Drives the Production of Tumor-Promoting Macrophages. Immunity 2013; 38:296-308; PMID:23333075; http://dx.doi.org/10.1016/j.immuni.2012.10.015
7. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin- I-converting enzyme protect against risk of cancer? Lancet 1998; 352:179-84; PMID:9683206; http://dx.doi.org/10.1016/S0140-6736(98)03228-0
8. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011; 12:65-82; PMID:21123111; http://dx.doi.org/10.1016/S1470-2045(10)70260-6
9. Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, et al. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol 2011; 107:1028-33; PMID:21256465; http://dx.doi.org/10.1016/j.amjcard.2010.11.026
10. Walker WG, Whelton PK, Saito H, Russell RP, Hermann J. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension 1979; 1:287-91; PMID:399240; http://dx.doi.org/10.1161/01.HYP.1.3.287